Lucy Gilbert, MD, MSc, FRCOG, discusses data from the ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
Lucy Gilbert, MD, MSc
Advertisement
Lucy Gilbert, MD, MSc, FRCOG, is a professor in the Department of Obstetrics and Gynecology and the Department of Oncology, as well as director of Gynecologic Oncology and director of the Women’s Health Research Unit at McGill University and the McGill University Health Centre
Articles by Lucy Gilbert, MD, MSc
Lucy Gilbert, MD, discusses overall survival data with relacorilant plus nab-paclitaxel based on prior taxane use from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer.
Lucy Gilbert, MD, MSc, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.
Lucy Gilbert, MD, MSc, discusses the safety profile of mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
5